Biotest GmbH & Co. KGaA (FRA:BIO1)

Market Cap	1.48B
Revenue (ttm)	635.20M -18.8%
Net Income	-24.50M
EPS	-0.63
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	42.20
Previous Close	42.20
Day's Range	42.20 - 42.20
52-Week Range	40.00 - 42.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About Biotest GmbH & Co. KGaA

Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalov...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,495
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BIO1

Financial Performance

In 2024, Biotest GmbH & Co. KGaA's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.